Research Grants


 
ONGOING
  • Bill & Melinda Gates Foundation - Xenodiagnosis of Visceral Leishmaniasis, Post Kala-azar Dermal Leishmaniasis and Asymptomatic subjects using Phlebotomine Sand Flies – 31 million rupees (2015-2018)
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA, - Visceral Leishmaniasis in Bihar State, India - 146 Million rupees (2007-12) and 130 million rupees (2012-17), 180 million rupees (2017-2022).
  • The Foundation for the National Institutes of Health (FNIH), USA  - Epidemiology of Visceral Leishmaniasis in Muzaffarpur District, Bihar (Epi VL) – 5.7 million rupees (2014-2016).
  • Department of Science and Technology, Government of India Nano project - Synthesis and application of nano materials towards energy and EMI shielding, targetted drug delivery and theranostic application of biocompatible micro particle derived from human platelet for nano therapeutics.
 
COMPLETED
 
  • Indo-Australian Biotechnology Fund: - Designing combination immunotherapy and drug treatment to control chronic infectious diseases -14 million rupees.
  • European Commission: - New tools for monitoring drug resistance and treatment response in Visceral Leishmaniasis in the Indian subcontinent ( KALADRUG-R) – 25 million rupees
  • World Health Organisation/Tropical Diseases Research: - A Evaluation of Health System in Delivering Health Care in Visceral Leishmaniasis – 2.4 million rupees
  • Indian Council of Medical Research: - Comparative Evaluation of PCR Primers In Diagnosis and Prognosis of Indian Visceral Leishmaniasis (VL) and Post Kala-Azar Dermal Leishmaniasis (PKDL) – 2 million rupees
  • European Commission: - Efficacy, acceptability and cost-effectiveness of long lasting insecticide treated nets in the prevention of Kala-azar – 25 million rupees
  • Infectious Diseases Rsearch Institute/Bill & Melinda Gates Foundation: - A phase I, open-label, dose-escalating study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine (recombinant three-antigen Leishmania polyprotein with adjuvant MPL-SE) in healthy adults in india – 6.5 million rupees
  • World Health Organisation/Tropical Diseases Research: -
-        A Phase III Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of injectable Paromomycin in Patients with Visceral Leishmaniasis.
-        Field Evaluation of novel diagnostic tests for Visceral Leishmaniasis: freeze dried DAT, rK39, rK26 dipsticks and KAtex (latex agglutination urine test)
-        Visceral Leishmaniasis and PKDL in India: New Therapeutic, Immunologic and Diagnostic Studies, and Site Preparation for Vaccine Trial - a multiinstitutional project involving BHU, CDRI, IICB and RMRI (Project Leader – Dr Shyam Sundar)
-        “Treatment of visceral leishmaniasis with the orally administrable agent miltefosine: a rising dose, phase II trial”
-        "Immunochemotherapy for visceral leishmaniasis interferon-gamma plus antimony"
-        A Phase III Clinical trial to assess efficacy and safety of orally administered miltefosine in children with visceral leishmaniasis
-        A Study of HIV/VL Co-infection A Phase III Clinical trial to assess efficacy and safety of orally administered miltefosine in patients with visceral leishmaniasis with Control group: Amphotericin B
-        A phase II trial of short course amphotericin B and Fat emulsion in the treatment of Indian kalaazar
-        A multicenter phase II trial of miltefosine in Indian Visceral Leishmaniasis.
-        A Phase II Clinical trial to assess efficacy and safety of orally administered miltefosine in children with visceral leishmaniasis
  • Joint Indo-US Vaccine Action Programme: -  "Immunologic and parasitologic studies of Indian Visceral Leishmaniasis" NIH/National Institute of Allergy and Infectious Diseases
    Bethesda, MD, USA AND DEPARTMENT OF BIOTECHNOLOGY, GOVT OF INDIA
  • Rockefeller Foundation, New York, USA : - "Immunochemotherapy for Indian visceral leishmaniasis: randomized controlled three-arm trial of treatment with 30 days of antimony alone vs. 30 days of antimony plus interferon-g vs. 15 days of antimony plus interferon-t."
  • Indian Council of Medical Research : - "Effect of recombinant human gamma interferon therapy in antimony resistant kala-azar - a clinical and immunological study"